Ophthalmic Backgrounds Influencing the Efficacy of SGLT2 Inhibitor in Diabetic Macular Oedema: Post‐hoc Analysis of the COMET Trial

R.I. has received research funding from Taisho Pharmaceutical Co. Ltd.; Astellas Pharma Inc.; Otsuka Pharmaceutical Co. Ltd.; AstraZeneca K.K.; Eli Lilly Japan K.K.; and Novo Nordisk Pharma Ltd. M.K. and K.Y. have received research support from Astellas Pharma Inc. and Taisho Pharmaceutical Co. Ltd. T.T. has received funding from Bayer Yakuhin Ltd. The other authors declare no conflicts of interest. Access to study data is subject to authorization by the clinical research ethics board of Chiba University Hospital and requires documented patient consent. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70831. Table S1: Baseline characteristics. Table S2:. Additional ANCOVA models. Figure S1:. CONSORT flow diagram for patient selection. Figure S2:. Forest plot of adjusted mean differences in IVR injection frequency across subgroups. Data S1: Supporting Information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.